Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2017 07:00 ET | Source: Stemline Therapeutics

Stemline Therapeutics Announces Completion of Enrollment in Stage 3 of the SL-401 Pivotal Trial in BPDCN

NEW YORK, March 23, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
March 16, 2017 19:25 ET | Source: Stemline Therapeutics

Stemline Therapeutics Reports Fourth Quarter 2016 Financial Results

NEW YORK, March 16, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
March 10, 2017 07:00 ET | Source: Stemline Therapeutics

Stemline Therapeutics to Present at the 29th Annual ROTH Conference

NEW YORK, March 10, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
March 02, 2017 11:31 ET | Source: Stemline Therapeutics

Stemline Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference

NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
February 21, 2017 07:00 ET | Source: Stemline Therapeutics

Stemline Therapeutics Provides Update on Clinical Programs

NEW YORK, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
February 02, 2017 15:24 ET | Source: Stemline Therapeutics

Stemline Therapeutics Provides Update on Pivotal BPDCN Trial

NEW YORK, Feb. 02, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, provides an update on its...
January 20, 2017 09:00 ET | Source: Stemline Therapeutics

Stemline Therapeutics Prices $45 Million Public Offering of Common Stock

NEW YORK, Jan. 20, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced the pricing...
January 19, 2017 16:03 ET | Source: Stemline Therapeutics

Stemline Therapeutics Announces Proposed Public Offering of Common Stock

NEW YORK, Jan. 19, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced that it...
January 09, 2017 17:15 ET | Source: Stemline Therapeutics

Stemline Therapeutics Announces Date Change for the Company’s Presentation at the 35th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline’s CEO, will now present at the 35th Annual J.P. Morgan...
January 09, 2017 10:30 ET | Source: Stemline Therapeutics

Stemline Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline’s CEO, will present at the 35th Annual J.P. Morgan...